Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 14.4% in December

Gyre Therapeutics, Inc. (NASDAQ:GYRE) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 952,300 shares, an increase of 14.4% from the December 15th total of 832,200 shares. Based on an average trading volume of 94,200 shares, the short-interest ratio is currently 10.1 days. Currently, 4.4% of the shares of the company are short sold.

Gyre Therapeutics Price Performance

NASDAQ:GYRE traded up $0.15 during mid-day trading on Friday, reaching $10.95. 48,956 shares of the company’s stock were exchanged, compared to its average volume of 116,811. Gyre Therapeutics has a one year low of $8.26 and a one year high of $26.37. The business’s fifty day simple moving average is $11.57 and its two-hundred day simple moving average is $12.64.

Insider Transactions at Gyre Therapeutics

In other news, President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $12.70, for a total transaction of $25,400.00. Following the completion of the sale, the president now owns 2,928,467 shares of the company’s stock, valued at approximately $37,191,530.90. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 16,054 shares of company stock worth $185,897 over the last quarter. Company insiders own 19.52% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Barclays PLC boosted its stake in shares of Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after buying an additional 6,855 shares during the period. Geode Capital Management LLC lifted its position in shares of Gyre Therapeutics by 16.9% during the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after acquiring an additional 43,840 shares during the period. State Street Corp grew its holdings in shares of Gyre Therapeutics by 8.8% during the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after purchasing an additional 8,412 shares in the last quarter. FMR LLC bought a new position in shares of Gyre Therapeutics in the third quarter worth $47,000. Finally, Advantage Alpha Capital Partners LP acquired a new position in Gyre Therapeutics in the third quarter valued at about $334,000. 23.99% of the stock is owned by institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.